In conclusion, X66, a novel HSP90 inhibitor, which binds to the N-terminal domain of HSP90, causes the degradation of client proteins and growth inhibition of tumor cells both in vitro and in vivo. The gene discussed is HSP90AA1; the disease is neoplasm.